RTI Health Solutions, Research Triangle Park, NC 27709, USA.
Novartis, East Hanover, NJ 07936-1080, USA.
Future Oncol. 2021 Jun;17(17):2151-2167. doi: 10.2217/fon-2020-1193. Epub 2021 Mar 12.
Adverse events (e.g., pyrexia) may affect treatment patterns and adherence. This study explored pyrexia risk tolerance among melanoma patients when treatment benefit is unknown versus known. US respondents with stage III (n = 100) or stage III unresectable/stage IV melanoma (n = 125) chose between hypothetical melanoma treatments, defined by reoccurrence/progression-free survival and pyrexia risk, one resembling standard-of-care and one resembling dabrafenib + trametinib. Respondents chose first when efficacy was unknown and then when efficacy was known; pyrexia risk was varied systematically to define maximum acceptable risk. Maximum acceptable risk of pyrexia was statistically significantly higher when efficacy was known versus unknown in stage III patients (85 vs 34%) and stage III unresectable/stage IV patients (66 vs 57%). Patients accepted higher levels of pyrexia risk when they understood treatment benefit.
不良反应（例如发热）可能会影响治疗模式和依从性。本研究旨在探究在治疗获益未知和已知的情况下，黑色素瘤患者对发热风险的耐受程度。美国的 III 期（n=100）或 III 期不可切除/IV 期黑色素瘤（n=125）患者在两种假设性的黑色素瘤治疗方案中进行选择，这两种方案根据无复发/进展生存和发热风险来定义，一种类似于标准治疗，另一种类似于达拉非尼联合曲美替尼。患者在疗效未知和已知时首先进行选择；系统地改变发热风险以确定最大可接受风险。在 III 期患者（85% vs 34%）和 III 期不可切除/IV 期患者（66% vs 57%）中，当疗效已知时，发热的最大可接受风险显著高于未知时。当患者了解治疗获益时，他们会接受更高水平的发热风险。
